This study demonstrates the potential utility of CK1α activators as WNT-inhibitors in the treatment of WNT-driven diseases like APC-associated polyposis, and provides compelling pre-clinical data to justify repurposing Pyrvinium for FAP patients in future clinical studies. Here, FAP is linked to polyposis.